US 12,280,066 B2
Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
Deng Pan, Chicago, IL (US); Masha Kocherginsky, Chicago, IL (US); and Suzanne D. Conzen, Park Ridge, IL (US)
Assigned to The University of Chicago, Chicago, IL (US)
Filed by The University of Chicago, Chicago, IL (US)
Filed on Dec. 15, 2023, as Appl. No. 18/541,675.
Application 18/541,675 is a continuation of application No. 17/577,882, filed on Jan. 18, 2022, granted, now 11,883,417.
Application 17/577,882 is a continuation of application No. 16/596,342, filed on Oct. 8, 2019, granted, now 11,234,990, issued on Feb. 1, 2022.
Application 16/596,342 is a continuation of application No. 15/448,827, filed on Mar. 3, 2017, granted, now 10,441,596, issued on Apr. 18, 2017.
Application 15/448,827 is a continuation of application No. 14/296,127, filed on Jun. 4, 2014, granted, now 9,623,032, issued on Apr. 18, 2017.
Application 14/296,127 is a continuation of application No. 14/172,051, filed on Feb. 4, 2014, granted, now 9,149,485, issued on Oct. 6, 2015.
Application 14/172,051 is a continuation of application No. 13/071,363, filed on Mar. 24, 2011, granted, now 8,710,035, issued on Apr. 29, 2014.
Claims priority of provisional application 61/317,182, filed on Mar. 24, 2010.
Prior Publication US 2024/0148754 A1, May 9, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/575 (2006.01); A61J 1/00 (2023.01); A61K 31/282 (2006.01); A61K 31/337 (2006.01); A61K 31/357 (2006.01); A61K 31/4745 (2006.01); A61K 31/567 (2006.01); A61K 31/58 (2006.01); A61K 31/7068 (2006.01); A61K 33/243 (2019.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61N 5/00 (2006.01)
CPC A61K 31/575 (2013.01) [A61J 1/00 (2013.01); A61K 31/282 (2013.01); A61K 31/337 (2013.01); A61K 31/357 (2013.01); A61K 31/4745 (2013.01); A61K 31/567 (2013.01); A61K 31/58 (2013.01); A61K 31/7068 (2013.01); A61K 33/243 (2019.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61N 5/00 (2013.01)] 12 Claims
 
1. A method of killing breast cancer cells comprising administering to a breast cancer patient an effective amount of a combination of anti-cancer compounds, wherein the anticancer compounds comprise a glucocorticoid receptor antagonist selected from beclometasone, betamethasone, budesonide, ciclesonide, flunisolide, fluticasone, mometasone, triamcinolone, mifepristone (RU-486), RU-43044, 10β-substituted steroids, 11β-aryl conjugates of mifepristone, phosphorous-containing mifepristone analogs, 11-monoaryl and 11,21 bisaryl steroids (including 11 (3-substituted steroids), octahydrophenanthrenes, spirocyclic dihydropyridines, triphenylmethanes and diaryl ethers, chromenes, dibenzyl anilines, dihyrdroquinolines, pyrimidinediones, azadecalins, aryl pyrazolo azadecalins (including 8a-benzyl isoquinolones, N-substituted derivatives, bridgehead alcohol and ethers, bridgehead amines, ORG-34517 (Merck), dexamethasone mesylate (Dex-Mes), dexamethasone oxetanone (Dex-Ox), deoxycorticosterone (DOC), CORT 0113083 and CORT 00112716,
and a chemotherapeutic agent.